High Dose LX2006 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 18 | 脊髄小脳変性症（多系統萎縮症を除く。） | 1 |
18. 脊髄小脳変性症（多系統萎縮症を除く。）
臨床試験数 : 76 / 薬物数 : 98 - (DrugBank : 31) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05445323 (ClinicalTrials.gov) | August 24, 2022 | 23/6/2022 | Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia | A Phase 1/2 Study of the Safety and Efficacy of LX2006 Gene Therapy in Participants With Cardiomyopathy Associated With Friedreich's Ataxia | Friedreich Ataxia;Cardiomyopathy, Secondary | Genetic: Low dose LX2006;Genetic: High Dose LX2006 | Lexeo Therapeutics | NULL | Recruiting | 18 Years | 40 Years | All | 10 | Phase 1/Phase 2 | United States |